Malaria Journal

Table 3 Summary of the four dosing trials described in this report

From: ELQ-331 as a prototype for extremely durable chemoprotection against malaria

Trial	Dose, prodrug	Time from dosing to testing
Trial	Dose, prodrug	Plasma [ELQ-300] determination	Blood stage challenge	Sporozoite challenge
1	30 mg/kg ELQ-331	47, 60, 90, 120 days	7, 14, 21, 40 days	137 days
	30 mg/kg ELQ-499
	30 mg/kg ELQ-500
2	30 mg/kg ELQ-331	6, 12, 18, 24, 36, 48, 72 h; weekly 1–10, 14, 18, 22, 24 weeks	n/a	48 days
3	10 mg/kg ELQ-331	30, 70, 77 days	n/a	77 days
	10 mg/kg ELQ-494	30, 70 days		n/a
	10 mg/kg ELQ-495	30, 70 days
	10 mg/kg ELQ-501	30, 83 days
4	2.5 mg/kg ELQ-331	14, 27 days	n/a	n/a
	5 mg/kg ELQ-331			29 days
	10 mg/kg ELQ-331			29 days

Back to article page

ISSN: 1475-2875

Contact us

Submission enquiries: journalsubmissions@springernature.com